Closer Look: Sun-Ranbaxy A Powerhouse But Sales Culture A Dilemma?
This article was originally published in PharmAsia News
The merger of Sun and Ranbaxy is seen as the most ideal combination to seize Indian market opportunities. But field force integration may pose a tough barrier as the two sides operate very different marketing strategies.
You may also be interested in...
Size Is Rewarded When Fostering Brand In India, But Pricing Has To Be Right: Elsevier Business Intelligence Webinar
MUMBAI - Becoming too big may have resulted in operational inefficiencies and deteriorating R&D output for global drug makers, but getting bigger may be a successful formula for branded generics businesses in emerging markets
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.